Artenga Inc.

Artenga Inc. is an Ottawa-based medical technology company focused on developing drug delivery platforms that integrate focused ultrasound with microbubble drug conjugates. The company's proprietary technology is designed to enable non-invasive, targeted delivery of biologic drugs to specific areas of the body, such as the brain, by temporarily and safely opening the blood-brain barrier. The platform utilizes microbubbles—commonly used in ultrasound imaging—which are functionalized to carry therapeutic payloads. This approach aims to enhance the delivery and absorption of treatments for serious conditions, including cancer and neurological disorders such as Parkinson's disease. The company's technical strategy includes the use of clinically scalable, covalent linkers to load large proteins onto microbubbles, providing a specialized method for therapeutic administration.

This technology is intended to address significant unmet medical needs by providing precise, localized treatment options that minimize systemic impact. Artenga has engaged in various collaborative research efforts, partnering with organizations such as the Sunnybrook Research Institute, the National Research Council of Canada, and the University of Helsinki. These collaborations have involved preclinical studies to evaluate the efficacy of their drug delivery platform in treating brain cell damage and enhancing chemotherapy. By focusing on non-invasive therapeutic delivery, Artenga aims to improve clinical outcomes for patients suffering from serious, challenging diseases. The company is led by founder and CEO James Keenan.